Cencora's stock plummeted by approximately 16.4% following a disappointing fiscal Q2, where it reported a revenue miss of $78.4 billion against analyst expectations of $81.04 billion. In response, the company has raised its full-year adjusted earnings guidance to $17.70-$17.90 and authorized a $2 billion share buyback, despite also cutting revenue growth projections from 7%-9% to 4%-6%. Analysts foresee a potential recovery in the upcoming quarter, aided by recent acquisitions and a renewed focus on margin expansion.
“Cencora, Inc. · is · global pharmaceutical sourcing and distribution services company · true”
“Cencora · distributes pharmaceutical products to · customers · nearly one-third of the industry”
“Cencora · is one of · leading domestic pharmaceutical wholesalers · 3”
“Cencora · holds over · percentage share of the US pharmaceutical wholesale industry · 90%”
“Cencora · expanded its international presence · year · 2021”
“Cencora · purchased · company · Alliance Healthcare”
“Cencora, Inc. Common Stock (COR) · current price · Cencora, Inc. Common Stock (COR) · $265.44”
“Cencora, Inc. Common Stock (COR) · closing price · Cencora, Inc. Common Stock (COR) · $265.44”
“Cencora, Inc. Common Stock (COR) · price change · Cencora, Inc. Common Stock (COR) · +0.69”
“Cencora, Inc. Common Stock (COR) · percentage change · Cencora, Inc. Common Stock (COR) · +0.26%”
“Cencora, Inc. Common Stock (COR) · bid price · Cencora, Inc. Common Stock (COR) · $255.00”
“Cencora, Inc. Common Stock (COR) · ask price · Cencora, Inc. Common Stock (COR) · $300.15”